How board room decisions impact healthcare delivery

Quality of care for heart attacks and other conditions is determined in large part by decisions made in a hospital’s board room, according to a story in The New York Times.

Studies show that hospital boards can improve quality and can make decisions associated with reduced mortality rates. They also can set expectations for a culture of high performance. However, not all boards succeed at leveraging their power.

Read more below:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.